B

BioMark Diagnostics Inc
SWB:20B

Watchlist Manager
BioMark Diagnostics Inc
SWB:20B
Watchlist
Price: 0.28 EUR 1.45%
Market Cap: 25.4m EUR

BioMark Diagnostics Inc
Investor Relations

BioMark Diagnostics, Inc. engages in development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-11-03. The Company’s cancer diagnostic solutions can help detect, monitor and assess treatment for cancer. Its cancer diagnostics technology platform leverages Omics and machine learning, which allows for early cancer detection. The firm is focused on bringing its cancer diagnostic kits and detection solution to commercialization standards. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The firm has developed a liquid biopsy metabolic panel assay. This metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Rashid Ahmed Maula Bux B.Sc., MBA
Founder, CEO, President & Director
No Bio Available
Ms. Guoyu Huang MBA
Chief Financial Officer
No Bio Available
Mr. Brian Kai-Ming Cheng B.Sc., M.Sc, M.Sc.
Chief Technical Officer & Independent Director
No Bio Available
Dr. Jeff Haince Ph.D.
GM & Chief Scientific Officer
No Bio Available

Contacts

Address
BRITISH COLUMBIA
RICHMOND
130 - 3851 Shell Rd
Contacts